Alcon Ag · SIX:ALC
Alcon — 39th Annual JP Morgan Healthcare Conference 2021
17 slides from Alcon's conference presentation, Jan 12, 2021
Slide 1: JP Morgan Healthcare Conference
JP Morgan Healthcare Conference Investor Presentation January 12, 2021 1
Slide 2: Legal Disclaimers
Legal Disclaimers Forward-Looking Statements This document contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward- looking statements can be identified by words such as: “anticipate,” “inte
Slide 3: We aspire to lead the world in eye care innovation
We aspire to lead the world in eye care innovation Commitment Pipeline fueled Close partnerships across to innovation for growth the eye care industry 100+ active projects and 35+ with with increased positive proof of concept or and with key investments in R&D under regulatory review research instit
Slide 4: Strong demographic tailwinds
Strong demographic tailwinds Increasing wealth Aging population with and growth from growing eye care needs emerging economies Population over age 60 Middle class will grow by ~1.7b will double by 2050 people in the next 10-15 years2 (>1b people)1 Innovation improving Myopia prevalence is growing; t
Slide 5: Making progress in 2020
Making progress in 2020 Completing Separation, Expanding Our Portfolio Protecting Our People, Continuing Transformation With Innovation Serving Our Customers • Transitioned several business- • Outperformed market growth with • Market-leading brand equity1 critical systems and processes new product l
Slide 6: Investing in growth
Investing in growth 6
Slide 7: Balancing near and long-term innovation
Balancing near and long-term innovation Research & Development Building our portfolio 60% • AT-IOL advancements • Novel SiHy contact lenses 50% • Toric and multi-focal lenses • Multi-Dose Preservative-Free • Surgical instrumentation 30% 20% Investing for the future 10% 10% 10% 10% • New IOL platform
Slide 8: Investing in high-growth markets and share opportunities
Investing in high-growth markets and share opportunities Fast Precision1 toric Vivity PanOptix Dailies Total1 toric* Systane MDPF Pataday Precision1 Market Growth Ngenuity Slow Argos biometer Low Market Share High Illustrative purposes only MDPF: Multi-Dose Preservative-Free * Not currently in marke
Slide 9: PanOptix: Driving Alcon's leadership in the AT-IOL category
PanOptix: Driving Alcon’s leadership in the AT-IOL category 2019 Year-over-Year Market Growth Total IOL 7% Total AT-IOL 11% Trifocal 12% PC-IOL Source: Alcon data on file AT-IOL Continued growth expected as the launch enters its second year in the US and Japan Initial launch underway in China Ideal
Slide 10: Vivity: AT-IOL performance with the ease of monofocal patient management
Vivity: AT-IOL performance with the ease of monofocal patient management 2019 Year-over-Year Market Growth Total IOL 7% Total AT-IOL 11% Non-diffractive 12% PC-IOL Source: Alcon data on file AT-IOL First and only non-diffractive Extended Depth of Focus (EDOF) lens in the US An estimated 2 to 3 out o
Slide 11: Precision1: Growing share in the fastest growing contact lens subcategories
Precision1: Growing share in the fastest growing contact lens subcategories 2020 Year-over-Year Market Growth -6% Total Contact Lens Dailies SiHy 3% Dailies SiHy Source: GfK POS Tracking, value percent changes vs. prior year, as of November 2020. Data represents 18 of 26 globally tracked markets Pre
Slide 12: Pataday & Systane: expanding Alcon's leadership in ocular health
Pataday & Systane: expanding Alcon’s leadership in ocular health 2019 Year-over-Year Market Growth Dry Eye 6% Preservative-Free Dry Eye 10% US OTC Ocular Allergy 5% Dry Eye & Source: Alcon data on file Note: Pataday made its OTC switch in 2020 Allergy Systane: #1 in artificial tears & #1 doctor reco
Slide 13: Surgical innovation engineered to deliver better outcomes
Argos Surgical innovation engineered to deliver better outcomes Pre-operative Diagnostics Argos Faster image acquisition and accuracy Improved precision of optical corneal tomography Intra-operative Equipment Ngenuity Ngenuity Increased 3D depth of field provides better visualization and ergonomics
Slide 14: Capital Allocation Priorities
Capital Allocation Priorities Invest in organic growth Invest in BD&L & M&A Return to shareholders Research & Development behind Agnostic to source of innovation Initiation of dividend in 2021 IOLs, surgical suite, contact lens and ocular health Bolt-on acquisitions and Payout policy of 10% of Core
Slide 15: Key takeaways
Key takeaways Healthy long-term growth fundamentals Leadership in markets with durable growth prospects Revenue growth coupled with smart expense management should enable strong operating leverage over the long-term Increasing investments in R&D to build innovative pipeline Expanded manufacturing ca
Slide 16: Serving doctors, patients and customers
Serving doctors, patients and customers See Brilliantly 16
Slide 17: Alcon
Alcon SEE BRILLIANTLY
Alcon — 39th Annual JP Morgan Healthcare Conference 2021 on 6ix